Bioinformatics, FDA Approval and Pharmacokinetics

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Bioinformatics

FDA Approval

Pharmacokinetics

Accelerating Drug Discovery Through Repurposing

DrugBank

FEBRUARY 12, 2025

This approach capitalizes on prior investments in R&D, mitigates risk by leveraging established safety and pharmacokinetic profiles, and accelerates the delivery of treatments to patients. In Silico Drug Repurposing Advances in bioinformatics and systems biology have fueled the rise of repurposing of in silico drugs.

Cell Based Assays

Cell Based Assays Drugs Pharmacokinetics Disease

Bristol Myers Squibb Announces Interim Results from Long-Term Study Reinforcing Efficacy and Safety Profile of Zeposia (ozanimod) in Patients with Relapsing Forms of Multiple Sclerosis

The Pharma Data

SEPTEMBER 1, 2020

Inhibition of drug transporter breast cancer resistance protein has no effect on the pharmacokinetics of major active metabolites of ozanimod. Presentation Topic: Biomarkers and Bioinformatics. Food and Drug Administration (FDA) approved Zeposia for the treatment of adults with relapsing forms of multiple sclerosis (RMS) in March 2020.

Clinical Trials

Clinical Trials Treatment Trials Disease

Webinars

Bridging Innovation & Patient Care: The Growing Role of AI

MORE WEBINARS

Drug Discovery Digest

Accelerating Drug Discovery Through Repurposing

Bristol Myers Squibb Announces Interim Results from Long-Term Study Reinforcing Efficacy and Safety Profile of Zeposia (ozanimod) in Patients with Relapsing Forms of Multiple Sclerosis

Webinars

Stay Connected